K
Kim Vettenranta
Researcher at University of Helsinki
Publications - 187
Citations - 4896
Kim Vettenranta is an academic researcher from University of Helsinki. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 34, co-authored 173 publications receiving 4003 citations. Previous affiliations of Kim Vettenranta include Helsinki University Central Hospital & Finnish Red Cross.
Papers
More filters
Journal ArticleDOI
Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.
Nina Toft,Nina Toft,Henrik Birgens,Jonas Abrahamsson,Laimonas Griskevicius,Helene Hallböök,Mats Heyman,Tobias Wirenfeldt Klausen,Olafur G. Jonsson,K. Palk,Kaie Pruunsild,Petter Quist-Paulsen,Goda Vaitkeviciene,Kim Vettenranta,Ann Åsberg,Thomas Frandsen,Hanne Vibeke Marquart,Hans O. Madsen,Ulrika Norén-Nyström,Kjeld Schmiegelow +19 more
TL;DR: A pediatric-based protocol is tolerable and effective for young adults, despite their increased frequency of higher risk features, with significant differences only for non-high risk groups.
Journal ArticleDOI
Clinical Outcome of Children With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005
Maurizio Aricò,Martin Schrappe,Stephen P. Hunger,William L. Carroll,Valentino Conter,Stefania Galimberti,Atsushi Manabe,Vaskar Saha,André Baruchel,Kim Vettenranta,Keizo Horibe,Yves Benoit,Rob Pieters,Gabriele Escherich,Lewis B. Silverman,Ching-Hon Pui,Maria Grazia Valsecchi +16 more
TL;DR: Clinical outcome of children and adolescents with Ph-positive ALL has improved with advances in transplantation and chemotherapy, and transplantations with matched related donors and unrelated donors were equivalent and offered better disease control compared with chemotherapy alone.
Journal ArticleDOI
Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years.
TL;DR: New, quicker and better diagnostic tests and more effective anti-fungal agents, both for prophylaxis and treatment, are needed for BMT patients at risk.
Journal ArticleDOI
Age- and Sex-Specific Incidence of Childhood Leukemia by Immunophenotype in the Nordic Countries
Lisa Lyngsie Hjalgrim,Klaus Rostgaard,Kjeld Schmiegelow,Stefan Söderhäll,Svein Kolmannskog,Kim Vettenranta,Jon Kristinsson,Niels Clausen,Mads Melbye,Henrik Hjalgrim,Göran Gustafsson +10 more
TL;DR: Investigation of time trends in the age- and sex-specific incidence of childhood acute leukemia during the last 20 years in the Nordic countries indicated an early increasing incidence of B-precursor acute lymphoblastic leukemia that corresponded to a simultaneous decreasing incidence of unclassified acute lymphblastic leukemia.
Journal ArticleDOI
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
Christina Peters,Jean-Hugues Dalle,Franco Locatelli,Ulrike Poetschger,Petr Sedlacek,Jochen Buechner,Peter J. Shaw,Raquel Staciuk,Marianne Ifversen,Herbert Pichler,Kim Vettenranta,Peter Svec,Olga Aleinikova,Jerry Stein,Tayfun Güngör,Jacek Toporski,Tony H. Truong,Cristina Diaz-de-Heredia,Marc Bierings,Hany Ariffin,Mohammed Sh. Essa,Birgit Burkhardt,Kirk R. Schultz,Roland Meisel,Arjan C. Lankester,Marc Ansari,Martin Schrappe,Arend von Stackelberg,Adriana Balduzzi,Selim Corbacioglu,Peter Bader +30 more
TL;DR: Improved OS and lower relapse risk were observed following TBI plus etoposide compared with chemoconditioning, and the futility stopping rule is applied, and patients > 4 years old with high-risk ALL undergoing allogeneic HSCT are recommended.